Cargando…

Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks

BACKGROUND: The fungal sesquiterpenes Illudin M and S are important base molecules for the development of new anticancer agents due to their strong activity against some resistant tumor cell lines. Due to nonspecific toxicity of the natural compounds, improvement of the pharmacophore is required. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaverra-Muñoz, Lillibeth, Briem, Theresa, Hüttel, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148526/
https://www.ncbi.nlm.nih.gov/pubmed/35643529
http://dx.doi.org/10.1186/s12934-022-01827-z
_version_ 1784717052633677824
author Chaverra-Muñoz, Lillibeth
Briem, Theresa
Hüttel, Stephan
author_facet Chaverra-Muñoz, Lillibeth
Briem, Theresa
Hüttel, Stephan
author_sort Chaverra-Muñoz, Lillibeth
collection PubMed
description BACKGROUND: The fungal sesquiterpenes Illudin M and S are important base molecules for the development of new anticancer agents due to their strong activity against some resistant tumor cell lines. Due to nonspecific toxicity of the natural compounds, improvement of the pharmacophore is required. A semisynthetic derivative of illudin S (Irofulven) entered phase II clinical trials for the treatment of castration-resistant metastatic prostate cancer. Several semisynthetic illudin M derivatives showed increased in vitro selectivity and improved therapeutic index against certain tumor cell lines, encouraging further investigation. This requires a sustainable supply of the natural compound, which is produced by Basidiomycota of the genus Omphalotus. We aimed to develop a robust biotechnological process to deliver illudin M in quantities sufficient to support medicinal chemistry studies and future preclinical and clinical development. In this study, we report the initial steps towards this goal. RESULTS: After establishing analytical workflows, different culture media and commercially available Omphalotus strains were screened for the production of illudin M.Omphalotus nidiformis cultivated in a medium containing corn steep solids reached ~ 38 mg L(−1) setting the starting point for optimization. Improved seed preparation in combination with a simplified medium (glucose 13.5 g L(−1); corn steep solids 7.0 g L(− 1); Dox broth modified 35 mL), reduced cultivation time and enhanced titers significantly (~ 400 mg L(−1)). Based on a reproducible cultivation method, a feeding strategy was developed considering potential biosynthetic bottlenecks. Acetate and glucose were fed at 96 h (8.0 g L(−1)) and 120 h (6.0 g L(−1)) respectively, which resulted in final illudin M titer of ~ 940 mg L(−1) after eight days. This is a 25 fold increase compared to the initial titer. CONCLUSION: After strict standardization of seed-preparation and cultivation parameters, a combination of experimental design, empirical trials and additional supply of limiting biosynthetic precursors, led to a highly reproducible process in shake flasks with high titers of illudin M. These findings are the base for further work towards a scalable biotechnological process for a stable illudin M supply. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01827-z.
format Online
Article
Text
id pubmed-9148526
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91485262022-05-30 Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks Chaverra-Muñoz, Lillibeth Briem, Theresa Hüttel, Stephan Microb Cell Fact Methodology BACKGROUND: The fungal sesquiterpenes Illudin M and S are important base molecules for the development of new anticancer agents due to their strong activity against some resistant tumor cell lines. Due to nonspecific toxicity of the natural compounds, improvement of the pharmacophore is required. A semisynthetic derivative of illudin S (Irofulven) entered phase II clinical trials for the treatment of castration-resistant metastatic prostate cancer. Several semisynthetic illudin M derivatives showed increased in vitro selectivity and improved therapeutic index against certain tumor cell lines, encouraging further investigation. This requires a sustainable supply of the natural compound, which is produced by Basidiomycota of the genus Omphalotus. We aimed to develop a robust biotechnological process to deliver illudin M in quantities sufficient to support medicinal chemistry studies and future preclinical and clinical development. In this study, we report the initial steps towards this goal. RESULTS: After establishing analytical workflows, different culture media and commercially available Omphalotus strains were screened for the production of illudin M.Omphalotus nidiformis cultivated in a medium containing corn steep solids reached ~ 38 mg L(−1) setting the starting point for optimization. Improved seed preparation in combination with a simplified medium (glucose 13.5 g L(−1); corn steep solids 7.0 g L(− 1); Dox broth modified 35 mL), reduced cultivation time and enhanced titers significantly (~ 400 mg L(−1)). Based on a reproducible cultivation method, a feeding strategy was developed considering potential biosynthetic bottlenecks. Acetate and glucose were fed at 96 h (8.0 g L(−1)) and 120 h (6.0 g L(−1)) respectively, which resulted in final illudin M titer of ~ 940 mg L(−1) after eight days. This is a 25 fold increase compared to the initial titer. CONCLUSION: After strict standardization of seed-preparation and cultivation parameters, a combination of experimental design, empirical trials and additional supply of limiting biosynthetic precursors, led to a highly reproducible process in shake flasks with high titers of illudin M. These findings are the base for further work towards a scalable biotechnological process for a stable illudin M supply. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01827-z. BioMed Central 2022-05-28 /pmc/articles/PMC9148526/ /pubmed/35643529 http://dx.doi.org/10.1186/s12934-022-01827-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Methodology
Chaverra-Muñoz, Lillibeth
Briem, Theresa
Hüttel, Stephan
Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks
title Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks
title_full Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks
title_fullStr Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks
title_full_unstemmed Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks
title_short Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks
title_sort optimization of the production process for the anticancer lead compound illudin m: improving titers in shake-flasks
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148526/
https://www.ncbi.nlm.nih.gov/pubmed/35643529
http://dx.doi.org/10.1186/s12934-022-01827-z
work_keys_str_mv AT chaverramunozlillibeth optimizationoftheproductionprocessfortheanticancerleadcompoundilludinmimprovingtitersinshakeflasks
AT briemtheresa optimizationoftheproductionprocessfortheanticancerleadcompoundilludinmimprovingtitersinshakeflasks
AT huttelstephan optimizationoftheproductionprocessfortheanticancerleadcompoundilludinmimprovingtitersinshakeflasks